Stockreport

Is Exelixis (EXEL) Using Zanzalintinib To Redefine Its Post-Cabometyx Oncology Strategy? [Yahoo! Finance]

Exelixis, Inc.  (EXEL) 
Last exelixis, inc. earnings: 2/25 04:05 pm Check Earnings Report
PDF This move highlights Exelixis' effort to broaden beyond Cabometyx by pairing its emerging asset with an established immunotherapy partner in a difficult-to-treat tumor [Read more]